Dendritic cell vaccines enhanced with genetic tools and combined with PD-1/PD-L1 blockers to improve cancer immunotherapy

The combined therapy of dual-bioengineered DC vaccines and anti-PD-L1 antibody therapy achieved complete tumor suppression.

• DC vaccines utilize the immune system to target and eliminate tumor cells but face challenges like limited efficacy and increased PD-L1 expression on tumors.
• Lipid nanoparticles were developed to deliver both OVA mRNA and siRNA targeting PD-L1 to dendritic cells.
• Dually bioengineered DC vaccines were tested in both preventative and treatment tumor models.
• The therapy effectively blocked PD-L1 upregulation on tumor cells and led to significant tumor suppression.
• Rechallenge experiments indicated the induction of long-lasting immune memory against cancer.

Simplified